In a study conducted at the M.D. Anderson Cancer Center, CB-derived NK cells engineered with a CD19-CAR, IL-15, and inducible caspase 9 (iCasp9), were administrated to CD19+ R/R NHL and chronic lymphocytic leukemia (CLL) patients (NCT03056339, Table 1). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.